Martin Reck Selected Research

necitumumab

6/2016	The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial.
1/2016	Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE).
7/2015	Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
3/2015	Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Martin Reck Research Topics

Disease

183	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/2022 - 03/2005
98	Neoplasms (Cancer) 03/2022 - 10/2003
47	Disease Progression 04/2022 - 10/2005
41	Lung Neoplasms (Lung Cancer) 03/2022 - 08/2006
20	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2022 - 01/2003
18	Neutropenia 01/2021 - 03/2007
17	Adenocarcinoma 10/2020 - 10/2007
11	Exanthema (Rash) 01/2022 - 11/2008
10	Neoplasm Metastasis (Metastasis) 01/2022 - 06/2012
10	Brain Neoplasms (Brain Tumor) 01/2022 - 10/2012
9	Febrile Neutropenia 01/2020 - 03/2007
7	Thrombocytopenia (Thrombopenia) 06/2016 - 09/2006
6	Fatigue 10/2020 - 03/2012
6	Malignant Mesothelioma 01/2019 - 04/2005
6	Diarrhea 11/2016 - 05/2006
6	Anemia 12/2014 - 03/2007
5	Pain (Aches) 10/2020 - 08/2006
5	Melanoma (Melanoma, Malignant) 05/2019 - 06/2012
4	Cough 10/2020 - 08/2006
4	Hypertension (High Blood Pressure) 01/2020 - 08/2014
4	Nausea 01/2018 - 11/2011
4	Sepsis (Septicemia) 02/2014 - 03/2010
3	Adenocarcinoma of Lung 02/2022 - 01/2016
3	Body Weight (Weight, Body) 12/2018 - 07/2015
3	Mesothelioma 01/2017 - 04/2005
3	Hemorrhage 10/2012 - 09/2009
2	COVID-19 01/2022 - 01/2020
2	Asthenia 01/2021 - 06/2012
2	Carcinogenesis 01/2021 - 01/2009
2	Dyspnea (Shortness of Breath) 10/2020 - 08/2006
2	Dermatitis 12/2019 - 06/2012
2	Pneumonia (Pneumonitis) 12/2019 - 02/2014
2	Ovarian Neoplasms (Ovarian Cancer) 10/2019 - 05/2015
2	Circulating Neoplastic Cells 06/2019 - 12/2013
2	Fibrosis (Cirrhosis) 01/2019 - 01/2018
2	Renal Cell Carcinoma (Grawitz Tumor) 11/2018 - 04/2016
2	Edema (Dropsy) 01/2018 - 01/2014
2	Colorectal Neoplasms (Colorectal Cancer) 01/2018 - 05/2015
2	Vision Disorders (Hemeralopia) 01/2018 - 01/2014
2	Acne Vulgaris 07/2015 - 11/2008

Drug/Important Bio-Agent (IBA)

38	PlatinumIBA 01/2022 - 01/2003
31	Carboplatin (JM8)FDA LinkGeneric 01/2022 - 08/2003
31	Docetaxel (Taxotere)FDA Link 07/2021 - 01/2008
28	Pemetrexed (MTA)FDA Link 10/2020 - 04/2005
27	ErbB Receptors (EGF Receptor)IBA 01/2022 - 03/2005
25	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2022 - 02/2006
24	Cisplatin (Platino)FDA LinkGeneric 01/2019 - 04/2005
23	Paclitaxel (Taxol)FDA LinkGeneric 01/2022 - 01/2003
21	Biomarkers (Surrogate Marker)IBA 04/2022 - 02/2010
21	B7-H1 AntigenIBA 01/2022 - 11/2016
21	Bevacizumab (Avastin)FDA Link 01/2022 - 03/2009
20	Immune Checkpoint InhibitorsIBA 03/2022 - 01/2015
20	RamucirumabIBA 01/2022 - 08/2014
18	nintedanibIBA 10/2020 - 06/2010
17	Tyrosine Kinase InhibitorsIBA 01/2022 - 03/2005
17	pembrolizumabIBA 01/2022 - 04/2016
17	NivolumabIBA 01/2022 - 07/2015
15	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 01/2009
14	IpilimumabIBA 01/2022 - 06/2012
13	Pharmaceutical PreparationsIBA 01/2022 - 04/2005
13	atezolizumabIBA 01/2022 - 08/2017
12	Gefitinib (Iressa)FDA Link 01/2017 - 03/2005
11	Monoclonal AntibodiesIBA 01/2018 - 03/2009
10	durvalumabIBA 01/2022 - 04/2016
10	Etoposide (VP 16)FDA LinkGeneric 01/2021 - 01/2003
10	Gemcitabine FDA Link 06/2016 - 09/2006
8	LigandsIBA 01/2022 - 05/2014
6	Proteins (Proteins, Gene)FDA Link 12/2019 - 12/2008
5	DNA (Deoxyribonucleic Acid)IBA 08/2020 - 12/2008
4	Anaplastic Lymphoma KinaseIBA 11/2021 - 11/2016
4	CrizotinibIBA 11/2021 - 01/2014
4	AntibodiesIBA 07/2019 - 09/2014
4	necitumumabIBA 06/2016 - 03/2015
3	Phosphotransferases (Kinase)IBA 12/2021 - 01/2017
3	RNA (Ribonucleic Acid)IBA 08/2020 - 09/2015
3	Immunoglobulin G (IgG)IBA 01/2020 - 01/2016
3	AntigensIBA 05/2019 - 05/2018
3	Angiogenesis InhibitorsIBA 01/2017 - 03/2015
3	Vinorelbine (Navelbine)FDA LinkGeneric 10/2015 - 09/2008
3	Sorafenib (BAY 43-9006)FDA Link 01/2012 - 09/2009
2	osimertinibIBA 04/2022 - 01/2017
2	Circulating Tumor DNAIBA 12/2021 - 01/2018
2	AfatinibIBA 01/2021 - 03/2014
2	Transforming Growth Factor beta (TGF-beta)IBA 01/2021 - 01/2019
2	Cell-Free Nucleic AcidsIBA 12/2020 - 01/2018
2	cyclopropapyrroloindoleIBA 11/2020 - 01/2019
2	130-nm albumin-bound paclitaxelIBA 04/2020 - 01/2020
2	avelumabIBA 01/2020 - 05/2018
2	Blood Proteins (Serum Proteins)IBA 12/2019 - 01/2012
2	SurvivinIBA 11/2019 - 05/2019
2	Immunoglobulins (Immunoglobulin)IBA 01/2018 - 10/2017
2	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2018 - 10/2017
2	EnzymesIBA 01/2018 - 01/2014

Therapy/Procedure

92	Therapeutics 03/2022 - 03/2005
84	Drug Therapy (Chemotherapy) 01/2022 - 04/2005
20	Immunotherapy 03/2022 - 01/2015
5	Radiotherapy 01/2020 - 10/2010
4	Chemoradiotherapy 01/2022 - 12/2018
3	Adjuvant Chemotherapy 01/2016 - 10/2015
3	Drug Tapering 01/2011 - 01/2010